Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Francisco Cervantes

Francisco Cervantes, MD, PhDPhoto Cervantes 1                                    

Hematology Department

Hospital Clínic

University of Barcelona

Barcelona, Spain

Dr Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic of Barcelona and Professor at the University of Barcelona. His scientific interest has been focused on the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology and treatment. As a result of the activity in this field, he has published over 300 articles in peer-review journals. He was co-author of the publications of the IRIS study that allowed the approval of imatinib as frontline treatment of CML, participated in the introduction of the second-generation tyrosine kinase inhibitors, and is a member of the expert panels of the European LeukemiaNet for CML and MPN treatment. In the MPN field, he was the leading author of the prognostic classification of primary myelofibrosis or IPSS. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for MPN Research and Treatment, the European LeukemiaNet, and the PETHEMA Spanish Collaborative Group.

Francisco Cervantes

 

Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic, in Barcelona, Spain, and associate professor at the University of Barcelona. His main scientific interest is the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published more than 190 articles in peer-review international journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology, Experimental Hematology, Haematologica, Cancer, Oncogene, Seminars in Oncology, and the European Journal of Haematology. In the CML field, Dr. Cervantes contributed to the elaboration of Sokal’s score, is a coauthor of the publications of the IRIS study, which established imatinib as first-line treatment for CML, has participated in the introduction of the second-generation tyrosine kinase inhibitors for patients resistant to imatinib, as well as in the authorship of the European LeukemiaNet recommendations for the treatment of CML. His more recent contributions in the field of the MPNs have been the elaboration of the new prognostic classification of primary myelofibrosis on behalf of the International Working Group for Myelofibrosis Research and Treatment, as well as several studies on the role of leukocyte and platelet activation in the thrombosis of MPN patients. At local level, he is the national coordinator of the CML studies within the collaborative PETHEMA Spanish group. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for Myeloproliferative Neoplasms Research and Treatment, the European Leukemianet, and the Spanish Society of Hematology.

Andreas Hochhaus, MD

hochhaus_andreas

Universitätsklinikum Jena

Jena, Germany

 

Andreas Hochhaus is a Professor of Internal Medicine, Hematology and Oncology and interim Head of the Department of Hematology and Medical Oncology at the University Medical Center Jena in Germany. He was awarded the Endowed Professorship for Leukemia Research from the German José Carreras Leukemia Foundation in 2007.

He has been interested in treatment optimization of chronic myelogenous leukemia (CML) and has been involved in the management of the randomized CML Studies I-IV of the German CML Study Group for more than 19 years. His special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML, and targeted therapy in a variety of neoplastic disorders.

Dr. Hochhaus is investigator for the nilotinib, dasatinib and bosutinib phase II and phase III studies, has been participating in imatinib phase II and III studies and is conducting trials of imatinib combined with pegylated interferon alpha, lonafarnib and everolimus.

He is a member of the European Hematology Association, the American Society of Hematology, the American Society of Clinical Oncology, the International Society of Hematology, the International Association for Comparative Research on Leukemia and Related Diseases, and the German Society for Hematology and Oncology. He has published over 240 peer-reviewed papers and is regularly invited to speak at national and international symposia.

Jan Geissler

 

jan_geissler_200wJan Geissler

Chair, LeukaNET / Leukämie-Online, Germany

Co-Founder, CML Advocates Network

 

In July 2001, Jan received his diagnosis of a rare cancer, Chronic Myeloid Leukemia (CML), at a routine check-up. He then joined a phase I/II clinical trial. As hardly any information on upcoming treatments was available in the German language, he started to simplify and translate medical publications into German language. In 2002, he started to publish them by founding the online patient community Leukämie-Online (http://www.leukaemie-online.de), which is one of the most frequented patient websites on leukemia in the German speaking Internet today. Leukämie-Online became a charitable organisation in Germany in 2006, with Jan being the Chair.

In 2007, Jan has co-founded the CML Advocates Network (http://www.cmladvocates.net) together with other CML patient groups from Israel, the UK and Czech Republic. The goal of the web-based platform is to get organisations connected that are supporting patients with Chronic Myeloid Leukemia. Today, members include 57 CML groups from all continents, sharing best practice in cancer patient advocacy and campaigning for better treatment and care of CML patients world wide.

Jan is also a co-founder of the European Cancer Patient Coalition (ECPC), a board member of the European Forum for Good Clinical Practice (EFGCP), and acts on a number of advisory boards.

In the International CML Foundation (iCMLf), Jan acts as Communications Coordinator and runs the foundation's Pediatric CML program.

Contact

Jan Geissler <jan@cml-foundation.org>

Susan Branford

 

Bio pic Branford 1Susan Branford, PhD, FFSc (RCPA)

Head, Leukaemia Unit
Genetics and Molecular Pathology
SA Pathology, Centre for Cancer Biology
An Alliance between SA Patholgy and The University of South Australia

Professor Susan Branford is Head of the Leukaemia lab in the Department of Genetics and Molecular Pathology at SA Pathology.

Sue has expertise in molecular monitoring of the BCR-ABL1 gene for patients with chronic myeloid leukemia. As such she is a major contributor to International collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data.

Dr Branford's research is focused on understanding the factors that predict response to tyrosine kinase inhibitor therapy and mechanisms of drug resistance.